SCHEMBL24019666

SCHEMBL24019666

CCC(=O)OCC(C)(C)Cc1cccc(Cl)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 1/20 0.45
EPHX2 P34913 2/20 0.42
HCAR2 Q8TDS4 1/20 0.41
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
TSHR P16473 1/20 0.41
MAOA P21397 2/20 0.40
MAOB P27338 2/20 0.40
MAPT P10636 1/20 0.40
MAPK1 P28482 1/20 0.40
PKM P14618 1/20 0.40
KMT2A Q03164 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
TAAR1 Q96RJ0 1/20 0.39
PDE3B Q13370 1/20 0.39
PDE3A Q14432 1/20 0.39
MMP1 P03956 1/20 0.39
MMP2 P08253 1/20 0.39
MMP9 P14780 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24112710 0.86 MAOB (0.45) RIPK1HCAR2KDM4EALDH1A1TSHR
SCHEMBL24740446 0.83 PNMT (0.43) RIPK1HCAR2ALDH1A1TSHRMAOA
SCHEMBL24112749 0.82 MAPT (0.43) RIPK1EPHX2HCAR2KDM4EALDH1A1
SCHEMBL13467287 0.79 HCAR2 (0.57) HCAR2KDM4EALDH1A1TSHRMAOA
SCHEMBL24019747 0.79 CTSL (0.47) RIPK1ALDH1A1TSHRMAPTKMT2A
SCHEMBL25769445 0.77 GRIN2D (0.43) RIPK1EPHX2KDM4EALDH1A1TSHR
SCHEMBL25759190 0.77 PNMT (0.42) RIPK1HCAR2ALDH1A1TSHRMAPT
SCHEMBL5287968 0.76 MAPT (0.44) RIPK1HCAR2KDM4EALDH1A1MAOB
SCHEMBL11974009 0.75 RIPK1 (0.49) RIPK1TSHRTAAR1CTBP2
SCHEMBL18473845 0.74 MMP8 (0.56) RIPK1HCAR2KDM4EALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. 2023-07-06 US disclosed
US-11174231-B1 Inhibitors of cysteine proteases and methods of use thereof Pardes Biosciences, Inc. (US) 2021-11-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11174231-B1 Inhibitors of cysteine proteases and methods of use thereof CTRL, CTSV, CTSL RIPK1 1042/4885EPHX2 1581/4885HCAR2 4453/4885
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF CTRL, CTSL, CTSV RIPK1 2050/4885EPHX2 989/4885HCAR2 4309/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.